Phathom Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 01 2025
0mins
Source: Newsfilter
Financial Performance: Phathom Pharmaceuticals reported net revenues of $28.5 million for Q1 2025, with over 390,000 prescriptions filled for VOQUEZNA, reflecting an 8% increase from the previous quarter despite seasonal challenges. The company is implementing cost reductions and organizational changes to achieve profitability by 2026.
Strategic Changes: The company announced leadership transitions and a workforce reduction of approximately 6% as part of a restructuring plan aimed at enhancing commercial execution and reducing operating expenses by $60 to $70 million in 2025.
Analyst Views on PHAT
Wall Street analysts forecast PHAT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PHAT is 27.67 USD with a low forecast of 26.00 USD and a high forecast of 29.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 14.980
Low
26.00
Averages
27.67
High
29.00
Current: 14.980
Low
26.00
Averages
27.67
High
29.00
About PHAT
Phathom Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases. The Company’s product candidates include VOQUEZNA, VOQUEZNA TRIPLE PAK, and VOQUEZNA DUAL PAK. Its product candidate, VOQUEZNA, contains vonoprazan, an oral small molecule potassium-competitive acid blocker, or potassium-competitive acid blocker (PCAB). PCABs are a novel class of medicines that block acid secretion in the stomach. Vonoprazan has also demonstrated clinical benefits in the treatment of erosive gastroesophageal reflux disease (erosive GERD), and in combination with antibiotics for the treatment of Helicobacter pylori (H. pylori) infection. GERD and H. pylori infection are two of the most common acid-related GI diseases. GERD is a disease that develops when the reflux of acidic stomach contents causes troublesome symptoms and/or complications. H. pylori is a bacterial pathogen.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
